EMEA-001214-PIP05-19
Table of contents
Key facts
Invented name |
Fasenra
|
Active substance |
Benralizumab
|
Therapeutic area |
Gastroentology-Hepatology
|
Decision number |
P/0388/2021
|
PIP number |
EMEA-001214-PIP05-19
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of eosinophilic esophagitis
|
Route(s) of administration |
|
Contact for public enquiries |
AstraZeneca AB
E-mail: paediatrics@astrazeneca.com |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|